Forvis Mazars, LLP is an independent member of Forvis Mazars Global, a leading global professional services network. Ranked among the largest public accounting firms in the United States, the firm’s 7,000 dedicated team members provide an Unmatched Client Experience® through the delivery of assurance, tax, and consulting services for clients in all 50 states and internationally through the global network.
Spatial biology research tools company.
Research Activities:
Wet lab assay development and dry lab engineering.
At Safety Partners, we redefine environmental health and safety (EHS) in the workplace and labs with innovative solutions tailored to your needs. Over 32 years in serving the life sciences, biotech, real estate, and light manufacturing industries, we continue to empower organizations to proactively manage risks and cultivate a culture of safety. From initial permitting to job safety analyses, to emergency response planning and safety training – our team of experts are fully dedicated to fostering secure work environments. Join us in revolutionizing safety management and protecting your most valuable assets – because your peace of mind is our priority.
BiologicsMD is a private drug discovery and development company that focuses on novel and highly targeted agonists and antagonists to the PTH/PTHrP receptor for advanced treatments in hair loss conditions, bone disorders and prevention of bone metastases. We are funded through Connecticut Innovations and private investors and are seeking our first institutional raise to complete our first in-human clinical trials that we believe could lead to an early exit. We have formed a close relationship with thought-leading physicians in alopecia from Yale University and other centers of excellence. Our lead program, BMD-1141 has been shown to reverse hair loss quickly in animal models of chemotherapy-induced alopecia and alopecia areata. Currently no reliable animal model of androgenetic alopecia (male pattern baldness) is available, but the mechanism by which BMD-1141 works clearly matches the mechanism that could reverse this common form of alopecia. Alhough a small company today, BiologicsMD is committed to building its presence in the State of Connecticut and contributing to the already robust biopharmaceutical ecosystem.
Research Activities:
BiologicsMD’s lead asset, BMD-1141, is a patent-protected, first-in-class hair cycle stimulator for the treatment of various types of non-scarring alopecia including alopecia areata, chemotherapy-induced alopecia, and androgenetic alopecia. BMD-1141 has a novel mechanism of action and is expected to promote hair growth more effectively, with subcutaneous dosing every 1-6 months, without the serious side effects of existing treatments.The pre-clinical data package for the treatment of alopecia includes multiple animal models, providing clear evidence of efficacy and safety. Importantly, the safety profile generated from in vitro and in vivo studies of BMD-1141 demonstrate no siginfiant risk factors. Related to the mechanism of action, BMD-1141, even at 10x the maximally efficacious dose, does not result in hypercalcemia. The manufacturing platform data includes formulations and long-term stability. BiologicsMD is currently in the process of raising their first institutional round of $17MM to fund a phase IA clinical trial in a population enriched with androgenetic alopecia subjects, and a phase IB clinical trial in alopecia areata patients. Upcoming research activities include clinical batch manufacturing and IND-enabling toxicology. Completion of these steps and the phase IA clinical trial is expected to take 27 months.
In Focus Consulting helps video production teams optimize creative operations, implement efficient systems, and achieve better results so you can focus on what you do best – create amazing content. Jesse Krinsky has over 20 years of experience producing video content in the life science industry, including managing video production and creative strategy for Thermo Fisher Scientific. Previous clients include GlaxoSmithKline, Amgen, Johnson & Johnson, Qiagen, Philips Healthcare, Specialists on Call, and more.
In addition to video production, In Focus Consulting specializes in strategic consulting services:
The American Cancer Society Cancer Action Network (ACS CAN) advocates for evidence-based public policies to reduce the cancer burden for everyone. We engage our volunteers across the country to make their voices heard by policymakers at every level of government. We believe everyone should have a fair and just opportunity to prevent, detect, treat, and survive cancer.
Since 2001, as the American Cancer Society’s nonprofit, nonpartisan advocacy affiliate, ACS CAN has successfully advocated for billions of dollars in cancer research funding, expanded access to quality affordable health care, and advanced proven tobacco control measures.
We stand with our volunteers—people whose lives have been impacted by cancer—rallying to demand change. Together, we’re working to make cancer a top priority for public officials and candidates at the federal, state, and local levels. By engaging advocates across the country to make their voices heard, ACS CAN influences legislative and regulatory solutions that will end cancer as we know it, for everyone.
Research Activities:
No single nongovernmental, not-for-profit organization in the US has invested more to find the causes and cures of cancer than the American Cancer Society (ACS). In fact, we’ve helped make possible almost every major cancer research breakthrough since 1946.
ACS CAN supports state initiatives that appropriate funding to support scientific research on cutting-edge treatments, cancer prevention and early detection and ways to reduce cancer disparities. ACS CAN will look for opportunities to increase appropriation dollars for biomedical research.
Maipl Therapeutics develops small molecule new drugs to treat endometriosis-related pain, idiopathic pulmonary fibrosis (IPF), and other conditions. The company’s platform is based on breakthrough FP antagonist (FPA) lead compounds licensed from Ferring Pharmaceuticals. The FPA leads are potent and highly selective inhibitors of prostaglandin F2α signaling, with therapeutics potentials for menstrual pain, fibrosis, and inflammatory conditions in which elevated F2α causes a detrimental effect. FPAs have virtually no impact on other essential prostaglandin functions, unlike NSAIDs and COX-2 that are associated with rare but serious GI, renal, and CV side effects. Maipl has the first-mover advantage in their focused therapeutic areas, and will continue to explore new indications.
RNAConnect was founded by innovators in the RNA community, for innovators in the RNA community. We provide superior enzymatic tools for visualizing and manipulating RNA, to enable the RNA community discover, create, and innovate in ways previously not possible.
Our lead product is UltraMarathonRT ™, a next generation, group II intron-encoded reverse transcriptase. As biotechnology and molecular medicine advance, more powerful tools are needed to accurately monitor and manipulate the complex RNA landscape of living systems. UltraMarathonRT unlocks this potential by reporting on the full transcriptomic complexity of RNA in cells and tissues under a broad set of real-world reaction conditions. Given its unmatched processivity, unwinding efficiency, low abundance RNA sensitivity, and low operating temperature, UltraMarathonRT is an essential component of the genomics toolkit.
KPS Life is a stand-alone, global functional service provider (“FSP”) that offers a clinical outsourcing solution to the Biopharmaceutical and Medical Device & Diagnostic sectors across all phases of clinical drug development. Their services include clinical monitoring, clinical monitoring oversight, clinical trial management, data management, biometrics, and medical writing. The KPS Life FSP model is a proven alternative to traditional staffing and full-service organization methodologies and affords sponsors the opportunity to contract dedicated, embedded resources to complement their clinical teams while maintaining brand identity and strategic control of assets.
Operating in six continents across the globe, KPS Life is committed to working together with its clients through a hands-on operating model rooted in a partnership approach. KPS Life has carved out a leadership position within the FSP market sector by providing customized and scalable solutions that improve the quality and execution of clinical trials while mitigating costs and increasing transparency for its clients.
Founded in 2006, KPS Life is institutionally backed by LongueVue Capital (“LVC”). LVC is an entrepreneur-centric New Orleans based private equity firm focused on partnering with management teams through both growth and controlled investments across a variety of sectors, healthcare being the largest.
Research Activities:
KPS Life currently partners with more than 30 Biopharmaceutical Sponsors in executing their clinical trials across multiple therapeutic areas (most notably Oncology, Rare Disease, Cardio, CNS, Dermatology, Immunology) within all phases of clinical research.
Waters Corporation is the world’s leading specialty measurement company focused on improving human health and well-being through the application of high-value analytical technologies and industry leading scientific expertise. Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Specialties include UPLC, HPLC, Chromatography, Mass Spectrometry, Informatics, Thermal Imaging, Chemistry, Analytical Standards & Reagents, Data Integrity, and Specialty Measurement.
Research Activities:
At Waters we are accelerating the benefits of pioneering science for a healthier, safer, and more sustainable world. Accelerating refers to the drive and passion Waters has to solve the problems that matter at scale so that more people can benefit sooner. Benefits refer both to those which are directly created by Waters’ products and innovations, to the benefit of Waters’ customers’ products and innovations on human health and well-being. Pioneering science is all about blazing new trails and doing things previously thought to be impossible. It inspires and brings new hope to people.
Waters Corporation is the world’s leading specialty measurement company focused on improving human health and well-being through the application of high-value analytical technologies and industry leading scientific expertise. Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Specialties include UPLC, HPLC, Chromatography, Mass Spectrometry, Informatics, Thermal Imaging, Chemistry, Analytical Standards & Reagents, Data Integrity, and Specialty Measurement.
Research Activities:
At Waters we are accelerating the benefits of pioneering science for a healthier, safer, and more sustainable world. Accelerating refers to the drive and passion Waters has to solve the problems that matter at scale so that more people can benefit sooner. Benefits refer both to those which are directly created by Waters’ products and innovations, to the benefit of Waters’ customers’ products and innovations on human health and well-being. Pioneering science is all about blazing new trails and doing things previously thought to be impossible. It inspires and brings new hope to people.